Stocks · News reference
Filed: 2026-07-24 AccNo: 0001280784-26-000035 Size: 876 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-07-30 AccNo: 0001280784-26-000043 Size: 892 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.
Read original at globenewswire-inc